1501 W. Beauregard
San Angelo, Texas 76901
Phone: (325) 658-7750
Fax: (325) 658-8381
Crisis: (800) 375-8965
or (325) 653-5933

Medical Disorders
Resources
Basic InformationLookupsLatest News
Health Tip: Dental Association Supports Fluoridated WaterAnother Legacy of Terror Attacks: MigrainesRain May Not Cause Achy Joints After AllDisrupted Sleep Linked to Increased Amyloid-β ProductionAtherosclerosis ID'd in Many Without CV Risk FactorsArtificial Intelligence Promising for CA, Retinopathy DiagnosesFirst Drug Approved for Rare Condition That Inflames Blood VesselsProtecting Your Health From Wildfire SmokeHealth Tip: Recognize Warning Signs of HypothermiaNew Hope for Kids With Multiple Food AllergiesFew Patients, Providers Discuss Costs of Glaucoma Medicationsβ-Cell Sensitivity to Glucose Impaired After Gastric BypassHow to Perk Up the Holidays for Hospital PatientsVigorous Exercise May Help Slow Parkinson's DiseaseIf Mom Has Rheumatoid Arthritis, Baby May Develop It, TooNew Gene Therapy May Be Cure for 'Bubble Boy' DiseaseAnother Gene Therapy Breakthrough Against HemophiliaPrenatal Sugar Intake May Increase Asthma Risk in OffspringObesity May Be Tied to Higher Rosacea Risk in WomenGot Scabies? Here's What to DoAre Women With Parkinson's at a Disadvantage?Bariatric Surgery Alters Liver Fatty Acid MetabolismORBIT Bleeding Risk Score Performs Best in A-FibHealth Tip: Prevent the Spread of NorovirusAre Good Kidneys Going to Waste?Metabolic Risk Factors Linked to Severe Liver DiseaseImpaired White Matter Integrity for Depression in Parkinson'sHave Eczema? No Need for Bleach Baths, Study SuggestsPowerful Clot-Busting Drugs Not Useful After Leg Blockages: StudyComing Soon: A Gel That Could Help Save Soldiers' EyesGene Therapy May Allow Hemophilia Patients to Go Without MedsThyroidectomy-Specific Quality Improvement Measures ID'dPatients OK With Fewer Opioids After Gallbladder SurgeryShhhh! Patients Are SleepingDiagnostic Mutations ID'd in Chronic Kidney Disease PatientsAntithrombotics Deemed Safe in Carpal Tunnel Release SurgeryLink Between Diabetes, Antibiotic Use Called Into QuestionHealth Tip: Diagnosing PneumoniaNoisy Commutes Could Cause Long-Lasting DamageThe Buzz on How Flies Spread DiseaseRisk of Surgical Complications Up for Overlapping Hip SurgeryOral Microbiome Composition Linked to Esophageal Cancer RiskSmartphone Pics Help Docs ID Kids' Skin ConditionEven Non-Heart Surgery May Harm Your HeartCan Scrotal Vein Condition Hike Heart Risks?Breathing Trouble May Follow Preemies to AdulthoodInformed Football Refs Better at Spotting Suspected ConcussionsGum Disease Tied to Yet Another Deadly IllnessRSNA: Weight Loss Via Exercise Alone Not Protective for KneesPhysicians Report High Rate of Uncontrolled Atopic Dermatitis
Questions and AnswersLinksBook Reviews
Related Topics

FDA Approves Device to Help Curb Cluster Headaches

HealthDay News
by -- Robert Preidt
Updated: Apr 19th 2017

new article illustration

WEDNESDAY, April 19, 2017 (HealthDay News) -- Cluster headaches, though rare, are among the most severe forms of headache a person can face.

But there's new hope for at least some patients. The U.S. Food and Drug Administration said it has approved a hand-held device to treat these attacks.

The noninvasive device, called gammaCore, works to reduce cluster headache pain by transmitting mild electrical stimulation to the vagus nerve through the skin on the neck. This is a large nerve that runs from the brain to the colon.

One headache specialist said effective therapies are needed.

Cluster headaches "can be devastating to a person," said Dr. Noah Rosen.

"Although they are uncommon, affecting about 1 in 2,000, they are severe, disabling and poorly understood," said Rosen, who directs Northwell Health's Headache Center in Great Neck, N.Y.

While certain medications such as sumatriptan (Imitrex) are used to quell headaches, they don't always work for cluster headaches.

"Attacks that occur six or more times a day can't effectively be treated with sumatriptan safely, given the maximum daily dosage," Rosen noted.

The newly approved device might offer an alternative for at least some patients with cluster headache, however.

The gammaCore technology is made by the U.S.-based neuroscience and technology company electroCore. FDA approval of gammaCore was based on two clinical trials that found the device was more effective than placebo in reducing cluster headache pain.

One trial of 85 patients with episodic cluster headache found that it reduced pain in about a third of patients compared to about 10 percent of those on placebo.

A second trial of 27 patients found that "a significantly higher percentage of attacks were pain-free" for people using the device compared to those on placebo -- meaning that their pain had ceased by 15 minutes after headache.

According to a company news release, "gammaCore was found to be safe and well-tolerated," with most side effects being "mild and transient."

There were some caveats, however. The device should not be used by patients with an active implantable medical device, such as a pacemaker, hearing aid implant or any implanted electronic device; those diagnosed with narrowing of the arteries; those who have had surgery to cut the vagus nerve in the neck; people with clinically significant high or low blood pressure or certain irregular heart rhythms; and children or pregnant women.

It should also not be used by patients with a metallic device such as a stent, bone plate or bone screw implanted in or near the neck, or patients who are using another medical device at the same time or any portable electronic device (for example, a mobile phone).

For some cluster headache patients, gammaCore "offers a hope for a different treatment approach," Rosen said, and "may be another option for this needful community."

Dr. Sami Saba is a neurologist at Lenox Hill Hospital in New York City.

He explained that cluster headaches are thought to arise because of an abnormality in the body's autonomic nervous system. GammaCore may work because it stimulates the vagus nerve, which "also modulates the autonomic nervous system," Saba explained.

In that sense, it may be treating the origins of the painful headaches, "as opposed to merely treating the symptoms," he said.

Still, Saba pointed out that the device did not help the majority of the participants in the two studies.

GammaCore is currently available in Europe and some other parts of the world, and is expected to be available in the United States later this year, according to the news release.

More information

The Migraine Trust has more on cluster headache.